A novel immune evasion mechanism of LMP-1, an EBV-primary oncogene, in nasopharyngeal Carcinoma

著者	Yoshizaki Tomokazu
journal or publication title	Advances in Oto-Rhino-Laryngology
volume	72
page range	157-159
year	2011-08-01
URL	http://hdl.handle.net/2297/29464

doi: 10.1159/000324780

A novel immune evasion mechanism of LMP-1, an EBV-primary oncogene, in nasopharyngeal carcinoma.

Tomokazu Yoshizaki

Division of Otolaryngology, Head and Neck Surgery,

Graduate School of Medical Science, Kanazawa University,

13-1 Takaramachi,

Kanazawa 920-8641,

JAPAN

e-mail: tomoy@med.kanazawa-u.ac.jp

Abstract

Nasopharyngeal carcinoma is an Epstein-Barr virus (EBV)-associated tumor. Viruses that are associated with malignant transformation have evolved unique mechanisms to interfere with this interaction to evade antiviral T-cell responses. EBV exploits many immune evasive strategies to successfully establish a latent infection in B cells. CD8⁺ T-cell responses to LMP-1 are generally very low and rarely detected in healthy virus carriers. Activation of the NF- κ B pathway by EBV-LMP-1 leads to an up-regulation of the MHC class I antigen-processing pathway. Paradoxically, LMP-1 itself induces a subdominant CD8⁺ T-cell response and appears to have evolved to avoid immune recognition. An expression of LMP-1 in human cells enhanced the *trans*-presentation of CD8⁺ T-cell epitopes, however, *cis*-presentation of LMP-1-derived epitopes was severely impaired. Deletion of the first transmembrane domain of LMP-1, which prevented self-aggregation, significantly enhanced *cis*-presentation of T-cell epitopes from this protein, whereas it lost its ability to up-regulate *trans*-presentation. These results delineate a novel mechanism of immune evasion, which renders a virally

encoded oncogene inaccessible to the conventional MHC class I pathway limiting its *cis*-presentation.

Epstein-Barr virus (EBV) exploits many immune evasive strategies to successfully establish a latent infection in B cells and epithelial malignant tumors such as nasopharyngeal carcinoma (NPC). Analysis of the role of individual EBV latent antigens in the regulation of antigen-processing genes indicated that latent membrane protein-1 (LMP-1) was sufficient to up-regulate expression of transporters associated with antigen processing and *trans*-presentation of MHC class I-restricted epitopes in B cells¹). Subsequent studies demonstrated that the immunomodulatory effects of LMP-1 are mediated through C-terminal activator regions (CTAR1 and CTAR2), which are involved in the induction of the nuclear factor- κ B (NF- κ B). At the same time, LMP-1 promotes invasion and metastasis through these intracellular activation domains²⁻⁴). Paradoxically, the population of CD8⁺ T-cell that responds to LMP-1 is generally very low and rarely detected in healthy virus carriers, suggesting that LMP-1 may limit its

cis-presentation through the MHC class I pathway. We have delineated a mechanism by which LMP-1 limits its self-presentation without compromising its ability to modulate *trans*-presentation of CD8⁺ T-cell epitope^{5, 6})

To assess *trans*-presentation of LMP-1, we transfected multiple LMP-1 sequences to epithelial cell lines. Although all LMP-1 variants up-regulated the expression of MHC class I on a human epithelial cell line, C33A, considerable activation of LMP-1-specific T cells was only evident after incubation with peptide-sensitized cells. In contrast, LMP-1 expression in C33A cells enhanced *trans*-presentation of CD8⁺ T-cell epitopes from another EBV-encoded membrane protein, LMP-2A. Collectively, these results suggested that, despite its capacity to up-regulate *trans*-presentation via the MHC class I pathway, LMP-1 limits its self-presentation to CD8⁺ T cells.

Much of the data presented are based on either stable or transient expression of LMP-1. To confirm these observations, we assessed endogenous presentation of LMP-1 epitopes in EBV-transformed LCLs. Although activation of LMP-2A specific T cells was evident after incubation with HLA-matched LCLs, very low levels of activation of T cells

specific for multiple LMP-1–encoded peptide epitopes was observed. Activation of LMP-1–specific T cells could be detected after incubation with peptide-sensitized LCLs. To investigate the mechanism for this immune evasion, we tested a series of LMP-1 expression vectors with mutations in the CTAR1 and/or CTAR2 domain; and a deletion mutant commencing at the second methionine of LMP-1 (Δ 1-43LMP-1-GFP), which removes the first trans-membrane domain. This domain has been shown to have immunomodulatory effect, and Δ 1-43LMP-1 has been used for expanding LMP-1-specific T cells. Although mutations within the CTAR domains had no impact on the presentation of LMP-1 epitopes, deletion of the first *trans*-membrane domain enhanced endogenous presentation of HLA class I–restricted epitopes. Consistent with previous studies, intracellular localization analysis using fluorescent microscopy revealed that, although full-length LMP-1 and its CTAR mutants formed large aggregates in the perinuclear region, Δ 1-43LMP-1-GFP lost its ability to aggregate. This enhanced presentation was not the result of increased expression of Δ 1-43LMP-1-GFP compared with full-length LMP-1. These observations indicate that, although the NF- κ B signaling domains had no impact on *cis*-presentation of LMP-1 epitopes, aggregation of

this protein (a critical requirement for *trans*-presentation) limits its accessibility to the MHC class I processing machinery.

The data presented in this meeting indicate that, in addition to constraining its *cis*-presentation through aggregation, epitopes encoded within LMP-1 protein are most probably destroyed by cellular proteasomes, providing a dual strategy by which LMP-1 limits self-presentation to CD8⁺ T cells7).

Acknowledgement

In addition to the author, this work was contributed by Corey Smith, Naohiro Wakisaka, and Rajiv Khanna.

References

- 1) Rowe M, Khanna R, Jacob CA, et al. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinated up-regulation of peptide transporters and HLA-class I antigen expression. Eur J Immunol. 25:1374–1384, 1995

- 2) Yoshizaki T, Sato H, Furukawa M, Pagano J. The expression of matrix metalloproteinase 9 is enhanced by Epstein-Barr virus latent membrane protein 1. *Proc Natl Acad Sci USA* 95 : 3621-3626, 1998
- 3) Wakisaka N, Kondo S, Yoshizaki T, Murono S, Furukawa M, Pagano JS. Epstein-Barr Virus Latent Membrane Protein 1 Induces Synthesis of Hypoxia-Inducible Factor 1 {alpha}. *Mol Cell Biol.* 24:5223-5234, 2004
- 4) Kondo S, Seo SY, Yoshizaki T, Wakisaka N, Furukawa M, Joab I, Jang KL, Pagano JS. EBV latent membrane protein 1 up-regulates hypoxia-inducible factor 1alpha through Siah1-mediated down-regulation of prolyl hydroxylases 1 and 3 in nasopharyngeal epithelial cells. *Cancer Res.* 66:9870-9877, 2006
- 5) Khanna R, Burrows SR. Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases. *Annu Rev Microbiol.* 54:19–48, 2000
- 6) Smith C, Cooper L, Burgess M, et al. Functional reversion of antigen-specific CD8+ T cells from patients with Hodgkin lymphoma following in vitro stimulation with recombinant polyepitope. *J Immunol.* 177:4897–4906, 2006

7) Smith C, Wakisaka N, Crough T, Peet J, Yoshizaki T, Beagley L, Khanna R.

Discerning regulation of *cis*- and *trans*-presentation of CD8_ T-cell epitopes by

EBV-encoded oncogene LMP-1 through self-aggregation. Blood 113:6148-6152,

2009